6-苄基1-乙基6-氮杂螺[2.5]辛烷-1,6-二羧酸酯 | 147610-84-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-苄基1-乙基6-氮杂螺[2.5]辛烷-1,6-二羧酸酯
• 英文名称: 6-benzyl 1-ethyl 6-azaspiro[2.5]octane-1,6-dicarboxylate
• 英文别名: 6-O-benzyl 2-O-ethyl 6-azaspiro[2.5]octane-2,6-dicarboxylate
• CAS: 147610-84-2
• 化学式: C₁₈H₂₃NO₄
• 分子量: 317.385
• InChiKey: HPESIWGAJLAFOB-UHFFFAOYSA-N

物化性质

• 沸点：
  438.9±45.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-苄基1-乙基6-氮杂螺[2.5]辛烷-1,6-二羧酸酯 在 5%-palladium/activated carbon 盐酸 、 sodium hydroxide 、 氯化亚砜 、 水 、 氢气 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 dichlromethane 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 9.09h， 生成 2-[1-(4-cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]oct-6-yl]-N-methyl-acetamide
  参考文献：
  名称：

  WO2008/147314

  摘要：

  公开号：
• 作为产物：
  描述：

  三甲基碘化亚砜 、 4-(2-乙氧基-2-氧代亚乙基)哌啶-1-羧酸苄酯 在 potassium tert-butylate 作用下， 以 二甲基亚砜 为溶剂， 反应 2.0h， 以75%的产率得到6-苄基1-乙基6-氮杂螺[2.5]辛烷-1,6-二羧酸酯
  参考文献：
  名称：

  [EN] ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES
  [FR] COMPOSÉS INHIBITEURS DE CANAUX IONIQUES, FORMULATIONS PHARMACEUTIQUES, ET UTILISATIONS

  摘要：

  本发明主要针对新的化学实体，其主要抑制人类T型钙通道，并差异调节其他关键离子通道，以控制细胞兴奋性，以及参与持续性或慢性疼痛的发展和维持，和/或神经系统疾病的异常神经元活动。这些新颖化合物对治疗和预防这些离子通道参与的神经和精神疾病和疾病具有用处。该发明还涉及包含这些化合物的药物配方以及这些化合物的用途。

  公开号：

  WO2017083867A1

文献信息

• Spirocyclopropyl Piperidine Derivatives
  申请人：Bernstein Peter

  公开号：US20100168105A1

  公开（公告）日：2010-07-01

  Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

  本文公开了至少一种哌啶衍生物，至少一种药物组合物，其中包括本文所公开的至少一种哌啶衍生物，用于治疗至少一种与组织胺H3受体相关的疾病。
• Ion channel inhibitory compounds, pharmaceutical formulations, and uses
  申请人：AFASCI, Inc.

  公开号：US10562857B2

  公开（公告）日：2020-02-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and/or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明针对的新化学实体主要抑制人类 T 型钙通道，并对其他关键离子通道进行不同程度的调节，以控制细胞兴奋性和异常神经元活动，特别是与持续或慢性疼痛和/或神经紊乱的发展和维持有关的异常神经元活动。这些新型化合物可用于治疗和预防涉及这些离子通道的神经和精神疾病。本发明还涉及包含这些化合物的药物制剂以及这些化合物的用途。
• Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition
  作者：Dean G. Brown、Peter R. Bernstein、Andrew Griffin、Steve Wesolowski、Denis Labrecque、Maxime C. Tremblay、Mark Sylvester、Russell Mauger、Phillip D. Edwards、Scott R. Throner、James J. Folmer、Joseph Cacciola、Clay Scott、Lois A. Lazor、Mehrnaz Pourashraf、Vijayaratnam Santhakumar、William M. Potts、Simon Sydserff、Pascall Giguère、Carine Lévesque、Mohammed Dasser、Thierry Groblewski

  DOI：10.1021/jm4014828

  日期：2014.2.13

  A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only sigma 2 (62% at 10 mu M). Compound 6s demonstrated free-plasma exposures above the IC50 (similar to 50x) with a brain-to-plasma ratio of similar to 3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H-3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.
• ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES
  申请人：Afasci, Inc.

  公开号：EP3340988A1

  公开（公告）日：2018-07-04
• Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses
  申请人：AFASCI, Inc.

  公开号：US20180312471A1

  公开（公告）日：2018-11-01

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and/or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.